The centre for disease control and prevention (CDC) of the Chinese city of Jiaxin said in a social media statement that two doses of Chinese vaccine manufacturer Sinovac Biotech's experimental COVID-19 vaccine, CoronaVac, will cost USD29.75 per dose and that vaccinations for key groups, including medical professionals, have begun.
Chinese authorities have to date not released pricing details for potential COVID-19 vaccines. However, hundreds of thousands of people have been given experimental vaccines in late-stage trials as part of an emergency inoculation programme launched in July 2020.
According to Reuters, it was not clear if Jiaxin city's pricing includes subsidies.
Sinovac's vaccine is in late stage trials in Brazil, Indonesia and Turkey and the company has said that an interim analysis of Phase 3 trial data could come as early as November 2020.
Reportedly, Bio Farma, a state-owned firm in Indonesia which has reached a deal for at least 40 million doses from Sinovac, has said that the vaccine will cost around USD13.60 per dose when it becomes available in the country.
China has said that while reasonable profits for companies are permitted, COVID-19 vaccines should be priced close to cost, Reuters added.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine